Title: Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.
Journal: Toxicology letters 20180701
Title: Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
Journal: Blood 20160609
Title: Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.
Journal: Cancer research 20160301
Title: Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
Journal: Leukemia 20160101
Title: Better Together: Targeted Combination Therapies in Breast Cancer.
Journal: Seminars in oncology 20151201
Title: FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20151101
Title: Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Journal: Journal of the National Cancer Institute 20151001
Title: Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20150901
Title: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine 20150716
Title: Palbociclib Extends Survival in Advanced Breast Cancer.
Journal: Cancer discovery 20150701
Title: Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Journal: Cancer 20150501
Title: Palbociclib: first global approval.
Journal: Drugs 20150401
Title: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20150301
Title: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Journal: The Lancet. Oncology 20150101
Title: CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Journal: Cancer research 20140715
Title: Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Journal: Pigment cell & melanoma research 20140701
Title: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
Journal: Genes & cancer 20140701
Title: Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Journal: Molecular cancer therapeutics 20140401
Title: MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.
Journal: Cell cycle (Georgetown, Tex.) 20140301
Title: Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Journal: Molecules (Basel, Switzerland) 20140217
Title: [Effect of PD0332991 on biological activity of hematopoietic stem cells in mice].
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20140201
Title: Targeting cell cycle and hormone receptor pathways in cancer.
Journal: Oncogene 20131128
Title: Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
Journal: British journal of cancer 20131112
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Journal: Anticancer research 20130801
Title: A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Journal: Cancer biology & therapy 20130701
Title: Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
Journal: Cell cycle (Georgetown, Tex.) 20130615
Title: Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20130601
Title: Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.
Journal: Journal of neuro-oncology 20130101
Title: PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
Journal: PloS one 20130101
Title: The requirement for cyclin D function in tumor maintenance.
Journal: Cancer cell 20121016
Title: Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.
Journal: Cancer cell 20121016
Title: Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.
Journal: Molecular cancer therapeutics 20121001
Title: Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120901
Title: CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
Journal: Cell cycle (Georgetown, Tex.) 20120715
Title: Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
Journal: Cell cycle (Georgetown, Tex.) 20120715
Title: p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Journal: Neuro-oncology 20120701
Title: The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.
Journal: Cancer prevention research (Philadelphia, Pa.) 20120601
Title: Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Journal: Blood 20120517
Title: An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing.
Journal: Journal of neuro-oncology 20120501
Title: Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS.
Journal: Bioanalysis 20120501
Title: Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Journal: Journal of the National Cancer Institute 20120321
Title: [(18)F]FLT-PET imaging does not always 'light up' proliferating tumor cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120301
Title: Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120115
Title: A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.
Journal: Cancer cell 20111115
Title: Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis.
Journal: The Journal of biological chemistry 20111021
Title: Quantitative analysis of PD 0332991 in mouse plasma using automated micro-sample processing and microbore liquid chromatography coupled with tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111001
Title: Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.
Journal: Biochemical and biophysical research communications 20110916
Title: Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Journal: Molecular and cellular biology 20110701
Title: Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110701
Title: Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
Journal: British journal of cancer 20110607
Title: Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
Journal: Endocrine-related cancer 20110601
Title: A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer.
Journal: Oncogene 20110428
Title: Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110315
Title: [CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS].
Journal: Medecine sciences : M/S 20101201
Title: Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry.
Journal: Journal of pharmaceutical and biomedical analysis 20101102
Title: RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.
Journal: Cell cycle (Georgetown, Tex.) 20101015
Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Journal: Journal of medicinal chemistry 20101014
Title: Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
Journal: Oncogene 20100715
Title: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
Journal: Cancer cell 20100713
Title: Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20100622
Title: Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Journal: Gastroenterology 20100501
Title: Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
Journal: Cancer research 20100415
Title: The landscape of somatic copy-number alteration across human cancers.
Journal: Nature 20100218
Title: Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors.
Journal: European journal of medicinal chemistry 20100201
Title: Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.
Journal: Cancer research 20090515
Title: Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells.
Journal: Blood 20090319
Title: Treatment of growing teratoma syndrome.
Journal: The New England journal of medicine 20090122
Title: Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090101
Title: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Journal: Breast cancer research : BCR 20090101
Title: CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
Journal: Breast cancer research : BCR 20090101
Title: A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Journal: Cancer research 20080715
Title: Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Journal: Blood 20070915
Title: Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Journal: Cancer research 20070515
Title: Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
Journal: Blood 20060901
Title: A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
Journal: Cancer research 20060801
Title: Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition.
Journal: Journal of medicinal chemistry 20060629
Title: Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Journal: Molecular cancer therapeutics 20060501
Title: Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Journal: Current opinion in pharmacology 20050801
Title: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
Journal: Journal of medicinal chemistry 20050407
Title: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
Journal: Molecular cancer therapeutics 20041101
Title: Primary care pediatrics vs. family practice: a nonissue.
Journal: Israel journal of medical sciences 19830801
